Editas Medicine, Inc.

EDIT Healthcare Biotechnology

Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.

2.45 0.30 −10.91%
Market cap
$422.3M
P/E
0.0×
Fwd P/E
−2.7×
Dividend yield
—
F-score
2/9
Altman Z
−13.39
Beneish M
−2.46
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 4 2 3

+8 more TTM periods

ROE
(118.82%) (326.07%) (198.14%) (211.37%)
ROA
(33.02%) (52.76%) (60.61%) (75.51%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(48.58%) (119.51%) (132.07%) (167.36%)
Average Days of Receivables
21.16 24.45 136.70 63.98
Free Cash Flow per Share
(1.01) (1.44) (1.87) (2.00)
Free Cash Flow
(120.28) (140.66) (165.58) (180.55)
Capital Expenditures
(0.42) (0.16) (0.34) (0.94)
Other line items
Cash ROIC
(37.95%) (109.84%) (95.20%) (100.81%)
Accounts Receivable Turnover
28.38 24.95 2.58 11.24
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
180.74% 209.24% 222.00% 239.65%
Selling, General and Administrative Expense of Revenue
96.81% 120.85% 123.16% 118.37%
Share Based Compensation of Revenue
18.41% 23.58% 24.68% 25.64%
Interest Coverage
(18.65) (21.65) (25.93) (22.52)
Operating CF/Net income
1.62 1.29 1.03 0.90
Depreciation/Fixed assets
0.86 1.22 1.24 0.95
Capex/Depreciation
(0.19) (0.05) (0.08) (0.23)
Revenue per Share
0.39 0.40 0.46 0.51
Operating CF per Share
(1.00) (1.44) (1.86) (1.99)
Capex per Share
0.00 0.00 0.00 (0.01)
Capex to Sales
0.01 0.00 0.01 0.02

Fold the line items

Columns are period end dates